To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the cardiac safety of a single oral dose (400 mg) of
pacritinib compared to placebo on the QT calculated using the Fridericia correction (QTcF)
interval in healthy subjects.